Document is current
Any future updates will be listed below
-
Authors
Wu, Tong https://orcid.org/0000-0001-9968-9909
Cheng, Anthony Youzhi
Zhang, Yuexiu
Xu, Jiayu
Wu, Jinjun https://orcid.org/0000-0002-2379-1162
Wen, Li
Li, Xiao
Liu, Bei
Dou, Xiaoyang
Wang, Pingluan
Zhang, Linda
Fei, Jingyi https://orcid.org/0000-0002-9775-3820
Li, Jianrong
Ouyang, Zhengqing https://orcid.org/0000-0003-2842-8503
He, Chuan https://orcid.org/0000-0003-4319-7424
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1HG008935, R01HG012780)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM124998)
- License Information
-
More Information
Article History
Received: 23 February 2023
Accepted: 15 December 2023
First Online: 18 January 2024
Competing interests
: The University of Chicago has filed a patent application on KARR-seq. C.H. is a scientific founder, a member of the scientific advisory board and an equity holder of Aferna Green, Inc. and AccuaDX, Inc., and is a scientific co-founder and equity holder of Accent Therapeutics, Inc. T.W. is an equity holder of AccuaDX, Inc. The other authors declare no competing interests.
